Catalent Launches Accelerated U.S. Gene-to-Drug Substance Program for Complex Biologics
Catalent, Inc., a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, has announced the U.S. launch of an accelerated gene-to-drug substance program designed to help developers advance complex biologics from gene sequence to drug substance in as little as 10 months.
The new offering is intended for next-generation biologic molecules, including bispecific antibodies, multispecific antibodies and other complex biologic formats that can present additional development and manufacturing challenges compared with traditional monoclonal antibodies (mAbs). By combining Catalent’s GPEx® Lightning cell line development technology with integrated development and manufacturing workflows and a U.S.-based operational network, the company aims to provide customers with a more predictable route toward clinical supply.
The program expands Catalent’s existing accelerated development capabilities and complements its Rapid Antibody offering for conventional mAbs. That program is designed to support a gene-to-GMP drug substance timeline of as little as eight months.
With the new complex biologics program, Catalent is establishing a 10-month target for moving multichain and other next-generation molecules from gene sequence through bulk drug substance lot release. The company said the approach is designed to preserve much of the speed associated with its Rapid Antibody program while addressing the specialized requirements of more complex biologic molecules.
“For patients facing serious conditions, faster access to advanced biologics can be critical,” said David McErlane, Biologics Group President for Catalent. “With GPEx® Lightning and our integrated U.S. development and manufacturing network, Catalent is helping customers move complex antibodies through a defined, disciplined path to the clinic while preserving the speed expected of our Rapid Antibody program for traditional mAbs.”
Addressing the Growing Complexity of Biologic Pipelines
The biopharmaceutical industry has increasingly expanded beyond conventional monoclonal antibodies as developers pursue molecules capable of addressing multiple biological targets or mechanisms of disease.
Bispecific and multispecific antibodies are among the formats gaining attention because they can be engineered to interact with two or more targets. Other next-generation biologics may also involve multiple chains, specialized structures or more demanding manufacturing requirements.
While these molecules can offer potential therapeutic advantages, their complexity can create additional challenges during cell line development, process development, analytical characterization and manufacturing.
Catalent’s accelerated program is designed to address these requirements through an integrated workflow. Rather than treating individual development activities as disconnected steps, the company is combining cell line development, process development and manufacturing activities within a coordinated program.
The objective is to establish a defined timeline that can help drug developers plan clinical development activities with greater predictability.
For emerging biopharmaceutical companies in particular, development timelines can have significant implications for clinical trial planning, capital requirements and the ability to advance a molecule toward regulatory milestones. Accelerating the production of clinical drug substance may allow developers to move more efficiently from early research into clinical testing.
GPEx Lightning Technology at the Center of the Program
A key component of Catalent’s accelerated complex biologics offering is its GPEx® Lightning cell line development technology.
Cell line development is a critical stage in the production of biologic medicines. During this process, developers establish mammalian cell lines capable of producing the desired therapeutic protein at appropriate levels and with the required quality characteristics.
For complex molecules, this process can become more demanding because of the structural and biological characteristics of the molecule being produced. Multichain antibodies, for example, require appropriate expression and assembly of multiple components.
Catalent is using GPEx® Lightning as part of its effort to establish an accelerated and standardized pathway for these molecules.
The company said the new program combines this technology with integrated development and manufacturing workflows. The U.S.-based execution model is intended to reduce complexity across the development process and create a coordinated path from the original gene sequence to bulk drug substance.
By integrating activities within a defined program, Catalent aims to help developers minimize delays associated with transferring work between different organizations or disconnected development stages.
Three Key Milestones Within 10 Months
Catalent’s accelerated complex biologics timeline is structured around three customer-facing milestones.
The first milestone is the anticipated conditional release of the master cell bank by month seven. Establishing the master cell bank is an important step because it provides the controlled biological starting material used for subsequent manufacturing activities.
The second milestone is anticipated bulk drug substance shipment to Catalent’s drug product site by month nine. This stage represents the transition from development and manufacturing activities into preparation for downstream drug product operations.
The third milestone is anticipated bulk drug substance lot release by month 10. Lot release represents a critical quality milestone before material can move forward for its intended use.
Taken together, these milestones establish a structured development path for complex biologics and provide developers with defined points for planning and program management.
Catalent emphasized that the timeline is intended to provide a predictable framework rather than simply accelerate individual steps in isolation. Coordinating the different stages can help developers better align cell line development, process activities, manufacturing, analytical testing and drug product preparation.
Two Accelerated Development Pathways
Catalent’s expanded offering gives developers two primary accelerated pathways depending on the type of biologic being developed.
For traditional monoclonal antibodies, the company’s Rapid Antibody offering is designed around a targeted eight-month gene-to-GMP drug substance timeline.
For multichain complex molecules and other next-generation biologics, the newly launched program is designed around a targeted 10-month gene-to-GMP drug substance timeline.
This distinction recognizes the different technical requirements associated with conventional antibodies compared with more complex biologic formats.
The company said the two offerings provide customers with clear development pathways while allowing the timeline to be aligned with the characteristics of the molecule.
For developers working on bispecifics, multispecifics and other next-generation biologics, having a dedicated accelerated pathway could help address the additional complexity associated with these products without abandoning the need for speed.
Integrated Route Toward Clinical Supply
The new program is also designed to complement Catalent’s broader drug substance and drug product capabilities.
Drug substance manufacturing produces the active biological material that will ultimately be formulated and converted into the finished drug product. Drug product manufacturing can include formulation, filling and finishing activities required to prepare a medicine for clinical or commercial use.
By connecting its accelerated drug substance offering with drug product capabilities, Catalent aims to provide developers with an integrated route from gene sequence through bulk drug substance and toward fill-finish readiness.
This integrated approach may be particularly relevant for companies seeking to reduce the operational complexity associated with working with multiple suppliers.
Managing separate organizations for cell line development, process development, drug substance manufacturing and drug product production can introduce additional coordination requirements. An integrated CDMO model can potentially simplify project management by connecting these activities within a broader development network.
Catalent’s new program therefore extends beyond simply establishing a shorter manufacturing timeline. It is designed to create a coordinated development pathway that can support customers as their biologic programs progress toward clinical testing.
Supporting Next-Generation Biologic Development
The expansion comes as the biopharmaceutical industry continues to develop increasingly sophisticated therapeutic modalities.
Traditional mAbs remain an important category of biologic medicines, but developers are increasingly exploring molecules designed to engage multiple targets or biological pathways. Bispecific and multispecific antibodies are examples of these next-generation approaches.
Such molecules can require specialized development strategies because their molecular structures may be more complicated than those of conventional antibodies. Manufacturing processes must be designed to consistently produce material with the appropriate structure, purity and quality characteristics.
The ability to establish an efficient manufacturing process early in development can therefore be important for companies preparing to enter clinical trials.
Catalent’s accelerated program seeks to address this need by combining technology, manufacturing infrastructure and development expertise under a defined timeline.
The company’s U.S.-based execution is another component of the offering. By maintaining the activities within its U.S. development and manufacturing network, Catalent aims to provide customers with a coordinated operational pathway.
Potential Benefits for Biopharmaceutical Developers
For drug developers, particularly smaller biotechnology companies, reducing development time can have implications beyond getting material into production sooner.
Clinical development programs require significant financial investment, and delays in manufacturing can affect trial initiation and progression. Access to clinical-grade drug substance is essential before many programs can advance into later development stages.
A defined 10-month development framework could help companies establish clearer project plans and coordinate manufacturing milestones with clinical development schedules.
The approach may also support companies that are developing multiple programs simultaneously. As pipelines become more diverse and complex, developers increasingly need manufacturing partners that can accommodate different molecular formats while maintaining predictable timelines.
Catalent’s two-pathway approach is intended to address this need by providing an accelerated option for conventional mAbs and a dedicated pathway for complex biologics.
Building on Catalent’s CDMO Capabilities
The launch of the complex biologics program adds to Catalent’s existing capabilities across biologics development and manufacturing.
The company is positioning the new offering as an extension of its Rapid Antibody platform, rather than as a separate standalone service. The objective is to bring the same emphasis on speed and defined execution to biologics that require more sophisticated manufacturing approaches.
With the complex biologics program, Catalent is targeting a 10-month journey from gene sequence to bulk drug substance lot release. The pathway includes the master cell bank, drug substance manufacturing and shipment to a drug product site, creating a series of defined milestones for developers.
Ultimately, Catalent’s accelerated gene-to-drug substance program reflects the growing demand for development and manufacturing solutions capable of keeping pace with increasingly complex biologic pipelines. By combining GPEx® Lightning technology, integrated development workflows and U.S.-based manufacturing capabilities, the company aims to help developers move bispecifics, multispecifics and other next-generation molecules toward clinical supply more efficiently.
The new offering gives customers a targeted 10-month pathway for complex biologics while maintaining the company’s eight-month target for traditional monoclonal antibodies through its Rapid Antibody program. Together, the two programs are designed to provide a structured approach for advancing biologic candidates from gene sequence through GMP drug substance and toward drug product manufacturing and fill-finish readiness.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach.
Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.